1 unknown. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
Follow Neuroinflammatory Response: new trials by email Literature Review of Neuroinflammatory Response trials Research Report on Neuroinflammatory Response
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg - Covid19, Corona Virus Infection | Phase 1 | Unknown | Biomed Industries, Inc. | 45 | 2020-09-15 | 2020-07-21 |
COVID-19 (1) · Cognitive Dysfunction (1) · Coronavirus Infections (1) · Nerve Degeneration (1) · Neuroinflammatory Diseases (1) · Pneumonia (1) · Severe Acute Respiratory Syndrome (1)
Cognition Disorders (1) · Coronaviridae Infections (1) · Infections (1) · Inflammation (1) · Lung Diseases (1) · Mental Disorders (1) · Nervous System Diseases (1) · Neurocognitive Disorders (1) · Nidovirales Infections (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Pneumonia, Viral (1) · RNA Virus Infections (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1)
remdesivir (1)
United States (1)
Lloyd Tran, PhD (1)